Atopic dermatitis is a chronic skin condition for which a range of systemic treatments have recently been approved. A treat-to-target strategy has been developed previously alongside an algorithm to guide the management of patients with atopic dermatitis. Here, we review the strategy and algorithm in the context of the evolving therapeutic landscape, and identify areas for further refinement and development.

CEReSSEA 3279 Research Center in Health Services and Quality of Life Aix Marseille University Marseille France; Department of Dermatology University Hospital of La Timone Marseille France; Dermatology Department Assistance Publique Hôpitaux de Marseille APHM Marseille France

Department of Allergology and Dermatology UMC Utrecht National Expertise Center for Eczema Utrecht The Netherlands

Department of Dermatology and Allergy Technical University of Munich Munich Germany

Department of Dermatology and Allergy University Hospital Schleswig Holstein Campus Kiel Kiel Germany

Department of Dermatology and Skin Science University of British Columbia Vancouver Canada

Department of Dermatology and Venereology Aarhus University Hospital Aarhus Denmark

Department of Dermatology Copenhagen University Hospital Bispebjerg and Frederiksberg Copenhagen Denmark

Department of Dermatology Hospital General de Alicante Alicante Spain

Department of Dermatology Kyoto Prefectural University of Medicine Graduate School of Medical Science Kyoto Japan

Department of Dermatology Royal North Shore Hospital Sydney New South Wales Australia

Department of Medicine Section of Dermatology and Venereology University of Verona Italy

Innovaderm Research Montreal QC Canada

Institute of Clinical and Experimental Medicine Prague Czech Republic

St John's Institute of Dermatology Guy's and St Thomas' NHS Foundation Trust London UK; Department of Dermatology Kings College London UK

The University of Melbourne St Vincent's Hospital Melbourne Melbourne Australia; Probity Medical Research Skin Health Institute Melbourne Victoria Australia

See more in PubMed

Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. . Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol 2018; 32: 657–682. PubMed

Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. . Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol 2018; 32: 850–878. PubMed

De Bruin-Weller M, Biedermann T, Bissonnette R, Deleuran M, Foley P, Girolomoni G, et al. . Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol 2021; 101: adv00402. PubMed PMC

Larsen HH, Vittrup I, Ruge IF, Elberling J, Skov L, Ibler K, et al. . Severe and ChRonic Atopic dermatitis Treatment CoHort (SCRATCH): a Danish real-world evidence atopic dermatitis treatment registry. Acta Derm Venereol 2022; 102: adv00760. PubMed PMC

Bagel J, Nguyen TQ, Lima H, Jain N, Pariser DM, Hsu S, et al. . Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE). Dermatol Ther (Heidelb) 2022; 12: 1417–1430. PubMed PMC

Siegels D, Haufe E, Heinrich L, Werfel T, Weidinger S, Schmitt J; TREATgermany Study Group . Status report on the atopic dermatitis registry TREATgermany. Allergol Select 2021; 5: 274–286. PubMed PMC

Ariëns LFM, van der Schaft J, Spekhorst LS, Bakker DS, Romeijn GLE, Kouwenhoven TA, et al. . Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-week results from the Dutch BioDay registry. J Am Acad Dermatol 2021; 84: 1000–1009. PubMed

Abuabara K, Silverberg JI, Simpson EL, Paller AS, Eichenfield LF, Bissonnette R, et al. . International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale. BMJ Open 2020; 10: e039928. PubMed PMC

Thyssen JP, Vestergaard C, Deleuran M, de Bruin-Weller MS, Bieber T, Taieb A, et al. . European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis. J Eur Acad Dermatol Venereol 2020; 34: e839–e842. PubMed